November 3, 2014 / 4:30 PM / 3 years ago

BRIEF-Lundbeck's Abilify Maintena schizophrenia drug best in head-to-head study

COPENHAGEN, Nov 3 (Reuters) - H Lundbeck A/S says: ** A head-to-head study showed that patients treated with Lundbeeck’s Abilify Maintena (aripiprazole once-monthly) demonstrated a statistically significant improvement on the primary endpoint, quality-of-life measure, compared to those treated with paliperidone palmitate ** Discontinuations due to adverse events occurred in 10.8 percent of patients in the aripiprazole once-monthly group compared to 18.4 percent of patients in the paliperidone once-monthly group Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below